Myocardial Solutions Presents Two New Abstracts at Global Cardio-Oncology Summit 2018

TAMPA, F.L., September 29, 2018 – Two studies utilizing Myocardial Solutions’ MyoStrain® in were presented at the Global Cardio-Oncology Summit 2018 in Tampa, Florida on September 27-28. The two abstracts report on the interim results of the Adult Oncology Cardiotoxicity study (NCT03543228) at Marien Hospital in Hamburg, Germany and were presented by Dr. Henning Steen. The study utilizes MyoStrain’s segmental strain metrics to quantify changes in myocardial function in chemotherapy patients and guide cardioprotective treatment management.

More detail of the abstracts are listed below:

Title: Is segmental myocardial strain the only cardiac evaluation modality to show subtle changes in myocardial dysfunction early into the chemotherapeutic regimen? – An interim report (NCT03543228)

Citation: Gersak B, et al. Is segmental myocardial strain the only cardiac evaluation modality to show subtle changes in myocardial dysfunction early into the chemotherapeutic regimen? – An interim report (NCT03543228). Global Cardio-Oncology Summit 2018. (n=26)

Title: Can early initiation of cardioprotective treatment (CPT), guided by early detection of a decline in segmental myocardial strain, improve cardiac function in patients on a chemotherapeutic regimen? – An interim report (NCT03543228)

Citation: Gersak B, et al. Can early initiation of cardioprotective treatment (CPT), guided by early detection of a decline in segmental myocardial strain, improve cardiac function in patients on a chemotherapeutic regimen? – An interim report (NCT03543228). Global Cardio-Oncology Summit 2018. (n=20)